ASX:CSLBiotechs
Is CSL (ASX:CSL) Cheap On Tavneos Revocation Risk?
CSL (ASX:CSL) is back in focus after the European Medicines Agency’s committee recommended revoking the EU marketing authorisation for Tavneos. This has raised fresh questions about the CSL Vifor unit and the stock’s recent recovery.
See our latest analysis for CSL.
The Tavneos setback arrives after a sharp 27.21% 1 month share price return for CSL. However, this sits against a weaker backdrop, with the stock down 31.52% year to date and the 1 year total shareholder return declining 49.94%,...

